- ISIN
- CA4576375022
- CUSIP
- 457637502
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Nov 12, 2020
Highlights
- EPS (TTM)
- -$361.24
- Total Revenue (TTM)
- $663.87M
- Gross Profit (TTM)
- $68.19M
- EBITDA (TTM)
- -$180.69M
- Year Range
- $0.58 - $5.50
- ROA (TTM)
- -1.99%
- ROE (TTM)
- -2.63%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
INM Performance Chart
InMed Pharmaceuticals Inc. (INM) is up 43.4% since the beginning of the year. At $2 per share, INM is trading 72.4% below its 52-week high of $6. Investors who bought $1,000 worth of INM shares 5 years ago would now be looking at an investment worth $1.
Loading charts...
Returns By Period
InMed Pharmaceuticals Inc. (INM) has returned 43.40% so far this year and -54.22% over the past 12 months.
InMed Pharmaceuticals Inc.
- 1D
- -2.56%
- 1M
- 103.13%
- YTD
- 43.40%
- 6M
- 13.43%
- 1Y
- -54.22%
- 3Y*
- -60.99%
- 5Y*
- -74.70%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.74%
- 1M
- 4.90%
- YTD
- 10.35%
- 6M
- 10.28%
- 1Y
- 26.52%
- 3Y*
- 20.83%
- 5Y*
- 12.30%
- 10Y*
- 13.66%
INM Monthly Returns History
Based on dividend-adjusted daily data since Nov 12, 2020, INM's average daily return is -0.15%, while the average monthly return is -6.49%.
Historically, 31% of months were positive and 69% were negative. The best month was May 2026 with a return of +118.1%, while the worst month was Oct 2022 at -53.7%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 6 months.
On a daily basis, INM closed higher 42% of trading days. The best single day was Aug 20, 2024 with a return of +191.4%, while the worst single day was Sep 13, 2022 at -35.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 3.77% | -22.73% | -24.13% | 11.65% | 118.06% | -3.18% | 43.40% | ||||||
| 2025 | -35.02% | -4.55% | -29.59% | 43.73% | -16.31% | 30.52% | -25.23% | -8.64% | -1.35% | -14.16% | -29.26% | -20.30% | -77.64% |
| 2024 | -13.49% | 15.31% | -12.29% | -28.54% | 13.42% | -10.00% | -33.79% | 101.88% | -33.22% | 12.19% | -19.33% | 10.49% | -43.03% |
| 2023 | -8.91% | -27.72% | -18.80% | 11.11% | 11.67% | -30.86% | 20.89% | -26.70% | -14.75% | -30.88% | -9.05% | -5.45% | -79.41% |
| 2022 | -7.63% | -22.13% | 0.05% | -3.47% | -15.38% | -38.91% | -17.09% | -38.97% | 10.82% | -53.74% | -13.11% | -23.77% | -93.83% |
| 2021 | 27.96% | 0.24% | -21.80% | 13.33% | -21.12% | 7.80% | -12.26% | -20.79% | -20.81% | -12.86% | 24.59% | -31.05% | -60.18% |
Benchmark Metrics
InMed Pharmaceuticals Inc. has an annualized alpha of -43.08%, beta of 1.15, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since November 13, 2020.
- This stock participated in 226.15% of S&P 500 Index downside but only -112.68% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -43.08%
- Beta
- 1.15
- R²
- 0.02
- Upside Capture
- -112.68%
- Downside Capture
- 226.15%
Return for Risk
Risk / Return Rank
INM ranks 27 for risk / return — below 27% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for InMed Pharmaceuticals Inc. (INM) and compare them to S&P 500 Index.
| INM | Benchmark | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | -0.34 | 2.24 | -2.58 |
Sortino ratioReturn per unit of downside risk | 0.17 | 3.07 | -2.90 |
Omega ratioGain probability vs. loss probability | 1.02 | 1.41 | -0.39 |
Calmar ratioReturn relative to maximum drawdown | -0.66 | 2.93 | -3.59 |
Martin ratioReturn relative to average drawdown | -0.92 | 13.52 | -14.44 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the InMed Pharmaceuticals Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the InMed Pharmaceuticals Inc. was 99.98%, occurring on Mar 30, 2026. The portfolio has not yet recovered.
The current InMed Pharmaceuticals Inc. drawdown is 99.94%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2026 bear market2026 | -99.98%Mar 2026 | 5y 1mo | — | 5y 3moFeb 2021 - now |
2021 bear market2021 | -21.56%Jan 2021 | 1d | 22d | 23dJan 2021 - Feb 2021 |
2020 correction2020 | -17.82%Dec 2020 | 16d | 21d | 1mo 7dDec 2020 - Jan 2021 |
2021 correction2021 | -17.02%Feb 2021 | 1d | 6d | 7dFeb 2021 - Feb 2021 |
2020 correction2020 | -11.90%Nov 2020 | 5d | 6d | 11dNov 2020 - Nov 2020 |
Drawdown Indicators
| INM | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.98% | -56.78% | -43.20% |
Max Drawdown (1Y)Largest decline over 1 year | -84.11% | -9.10% | -75.01% |
Max Drawdown (3Y)Largest decline over 3 years | -97.77% | -18.90% | -78.87% |
Max Drawdown (5Y)Largest decline over 5 years | -99.96% | -25.43% | -74.53% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -99.94% | -0.74% | -99.20% |
Average DrawdownAverage peak-to-trough decline | -86.01% | -10.72% | -75.29% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 60.50% | 1.97% | +58.53% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of InMed Pharmaceuticals Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how InMed Pharmaceuticals Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for INM relative to other companies in the Biotechnology industry. Currently, INM has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with INM
Add InMed Pharmaceuticals Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with INM